SCHEMBL165764

SCHEMBL165764

O=C(O)NCCN1CCNCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.61
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
KDM4E B2RXH2 2/20 0.49
GAA P10253 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ANPEP P15144 1/20 0.45
ERAP2 Q6P179 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
RAD52 P43351 1/20 0.44
HTR4 Q13639 3/20 0.43
ALDH1A1 P00352 2/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
ITGB3 P05106 1/20 0.41
ITGA2B P08514 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM3 P20309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4069459 0.93 HSD17B10 (0.54) HSD17B10MEN1KMT2AKDM4EGAA
SCHEMBL14861110 0.89 HSD17B10 (0.49) HSD17B10MEN1KMT2AKDM4EGAA
SCHEMBL3954077 0.87 HSD17B10 (0.47) HSD17B10MEN1KMT2AKDM4ESIGMAR1
SCHEMBL25242155 0.86 HSD17B10 (0.47) HSD17B10MEN1KMT2AKDM4EGAA
SCHEMBL23673763 0.85 CXCR4 (0.49) HSD17B10MEN1KMT2AKDM4ESIGMAR1
SCHEMBL21065340 0.85 CA12 (0.48) MEN1KMT2AKDM4EALDH1A1CA12
SCHEMBL21070088 0.83 MEN1 (0.52) HSD17B10MEN1KMT2AKDM4EGAA
SCHEMBL10359623 0.82 HSD17B10 (0.59) HSD17B10MEN1KMT2AKDM4EGAA
SCHEMBL1021302 0.82 MEN1 (0.59) HSD17B10MEN1KMT2AKDM4EGAA
SCHEMBL10704880 0.82 HSD17B10 (0.59) HSD17B10MEN1KMT2AKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024107753-A2 TREATMENT OF ASCT2-DEPENDENT CANCERS NEUPHARMA, INC (US) 2024-05-23 WO claimed
US-20200354398-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2020-11-12 US claimed
EP-3453714-A2 CARDENOLIDE AND BUFADIENOLIDE 3-CARBONATE AND 3-CARBAMATE DERIVATIVES FOR THE TREATMENT OF CANCER AND COMPOSITIONS THEREOF Suzhou Neupharma Co., Ltd (CN) 2019-03-13 EP claimed
US-20170088580-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2017-03-30 US claimed
US-9527852-B2 Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation NEUROPORE THERAPIES, INC. (US) 2016-12-27 US claimed
US-9487524-B2 2016-11-08 US claimed
US-9018197-B2 Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use SUZHOU NEUPHARMA CO. LTD. (CN) 2015-04-28 US claimed
EP-2830608-A1 PHENYL-UREA AND PHENYL-CARBAMATE DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION Neuropore Therapies, Inc. (US) 2015-02-04 EP claimed
CN-103619865-A Certain chemical entities, compositions, and methods SUZHOU NEUPHARMA CO LTD 2014-03-05 CN claimed
WO-2013148365-A1 PHENYL-UREA AND PHENYL-CARBAMATE DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION NEUROPORE THERAPIES, INC. (US) 2013-10-03 WO claimed
CN-102656179-A Bufalin derivatives, pharmaceutical compositions and uses thereof SUZHOU NEUPHARMA CO LTD 2012-09-05 CN claimed
US-20120196842-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2012-08-02 US claimed
WO-2012027957-A1 BUFALIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF SUZHOU NEUPHARMA CO., LTD. (CN) 2012-03-08 WO claimed
WO-2026087635-A1 DIHYDRO BENZOXAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 WO disclosed
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-04-24 US disclosed
WO-2025049555-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL OERTH BIO LLC (US) 2025-03-06 WO disclosed
EP-1165545-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2002-01-02 EP disclosed
WO-2000058305-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2000-10-05 WO disclosed
US-3864345-A Process for preparing novel N-(piperazinylethyl)-carbamates DOW CHEMICAL COMPANY, THE 1975-02-04 US disclosed
US-3864345-A Process for preparing novel N-(piperazinylethyl)-carbamates DOW CHEMICAL COMPANY, THE 1975-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200354398-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS TP53, VHL, SGMS2 HSD17B10 944/4885MEN1 22/4885KMT2A 2329/4885
US-20170088580-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS TP53, VHL, SGMS2 HSD17B10 944/4885MEN1 22/4885KMT2A 2329/4885
US-20120196842-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS TP53, VHL, SGMS2 HSD17B10 944/4885MEN1 22/4885KMT2A 2329/4885
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS HSD17B10 3549/4885MEN1 798/4885KMT2A 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.